A High-Profile Break Up
The termination of PE Biosystem Group's acquisition of Third Wave Technologies has sprouted a number of unfounded rumors. But the reason seems to be what the companies initially said it was: A Department of Justice review of the merger for antitrust violations was taking longer than expected. With no end in sight to it and an uncertain outcome, the companies were losing business opportunities in a fast-moving field. Rather, they decided to continue to work together in an alliance, and have already established a joint venture that is one of the world's largest production facilities of oligonucleotides.
You may also be interested in...
When the FTC forced Pfizer/Pharmacia to divest Nastech's nasal apomorphine--a potential competitor of Pfizer's Viagra--Nastech managed what may be a unique solution: it got the product back, with additional financing-and in so doing, solved the very different problems of Pharmacia, Pfizer, the FTC, and itself.
Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.
Pfizer and BioNTech’s Comirnaty supply under existing agreements will continue as planned despite anticipated expansion into a new child sub-population in Europe.